ZEPOSIA (Celgene Pty Ltd)
Product name
ZEPOSIA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
196 (255 working days)
Active ingredients
ozanimod hydrochloride
Registration type
EOI
Indication
Ulcerative Colitis
ZEPOSIA (capsule) is now also indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biological therapy.